NGNE241220C30000
- 0.05
- -0.02-28.57%
Neurogene Newsroom
William Blair Maintains Neurogene(NGNE.US) With Buy Rating
William Blair Reaffirms Their Buy Rating on Neurogene (NGNE)
H.C. Wainwright Maintains Neurogene(NGNE.US) With Buy Rating, Maintains Target Price $55
Neurogene Price Target Maintained With a $55.00/Share by HC Wainwright & Co.
Neurogene Analyst Ratings
Positive Outlook on Neurogene's NGN-401 Despite Setback: Buy Rating Reaffirmed With $55 Price Target
TD Cowen Maintains Neurogene(NGNE.US) With Buy Rating
Stifel Maintains Neurogene(NGNE.US) With Buy Rating, Maintains Target Price $46
Stifel Maintains Neurogene(NGNE.US) With Buy Rating, Raises Target Price to $46
TD Cowen Maintains Neurogene(NGNE.US) With Buy Rating
Neurogene's Resilient Clinical Progress and Strong Financial Position Support Buy Rating
Neurogene Is Maintained at Outperform by BMO Capital
BMO Capital Maintains Neurogene(NGNE.US) With Buy Rating, Cuts Target Price to $60
A Quick Look at Today's Ratings for Neurogene(NGNE.US), With a Forecast Between $46 to $60
Neurogene Analyst Ratings
Positive Interim Clinical Data and Strategic Developments Justify Buy Rating for Neurogene
Positive Buy Rating for Taysha Gene Therapies Amidst Competitive Advantages Over Neurogene
Neurogene Price Target Raised to $72.00/Share From $45.00 by Leerink Partners
Neurogene (NGNE) Receives a Buy From Stifel Nicolaus
Baird Maintains Neurogene(NGNE.US) With Buy Rating, Raises Target Price to $72